Drug Trial Radar · NCT02331823
Research on New Regimens for Retreatment Pulmonary Tuberculosis
Last checked: Nov 19, 2026Latest source record: Jan 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
864
Planned (sponsor's estimate)
Start
Jun 2013
Primary completion
Dec 2015
Study completion Dec 2016
Sponsor
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai Center for Disease Control and Prevention; Jiangsu Province Centers for Disease Control and Prevention; Zhejiang University; Centers for Disease Control and Prevention
- First posted
- Jan 6, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, prospective study is performed to investigate the efficacy of new short-course regimen for retreatment pulmonary tuberculosis patients. To obtain optimized short-course regimen, decrease treatment cost and improve success rate.
Conditions
- Reinfection Pulmonary Tuberculosis
Interventions
Isoniazid Aminosalicylate TabletsDrug
a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
Streptomycin injectableDrug
standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- success rateTime frame: for arm A,the point is 5 month after treatment. For arm B,the time point is at the end of the 8 or 9 month's treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.